Primær immun trombocytopeni: Å leve med ITP
Selv om forløpet i de fleste tilfeller er kortvarig, kan blødningene som oppstår være alvorlige. Det er viktig å unngå medisiner som øker blødningsfaren mens sykdommen pågår. Eksempler på dette er acetylsalisylsyre (aspirin, albyl) og betennelsesdempende medisiner (eks.: naproxen, ibumetin). Også ved skader og ved operative inngrep, inkludert tannlegebesøk, skal man være oppmerksom på at blødningsfaren er økt.
I perioder med svært lave blodplatetall (mindre enn 20-30) må man være forsiktig og unngå kontraktidretter eller andre situasjoner som kan føre til hodeskader. Dette gis det grundig veiledning om i de enkelte tilfellene.
Dette dokumentet er basert på det profesjonelle dokumentet Primær immun trombocytopeni . Referanselisten for dette dokumentet vises nedenfor
- Gudbrandsdottir S, Frederiksen H, Birgens HS, et al. Nye behandlingsmuligheder ved primær immun trombocytopeni. Ugeskr Læger 2011; 173: 271. Ugeskrift for Læger
- Pruemer J. Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura. Am J Health Syst Pharm 2009; 66 (2 Suppl 2): S4-S10.
- Christiansen CF, Bahmanyar S, Ghanima W et al. Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for Romiplostim. EClinicalMedicine 2019. epub. doi:https://doi.org/10.1016/j.eclinm.2019.07.015
- Zeller B, Wormdal OM. Generell veileder i pediatri. Utredning og behandling av kronisk ITP (trombocytopeni). Sist oppdatert 01.01.2017. Siden lest 25.06.2024. www.helsebiblioteket.no
- Neunert C, Terrel DR, Arnold DM, et al . American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019; 3: 3829-3866. PMID: 31794604 PubMed
- Scully M. Immune thrombocytopenia. BMJ Best Practice. Last reviewed 24.05.2024. Siden lest 24.06.2024. bestpractice.bmj.com
- McKenzie CGJ, Freedman LGJ, Semple JW. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol 2013; 163: 10-23. pmid:23937260 PubMed
- Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021. pmid:33835768 PubMed
- Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-93. Blood
- Provan D, Stasi R, Newland AC, et al. International concensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-86. Blood
- Xin-Guang Liu, Yu Hou, Ming Hou. How we treat primary immune thrombocytopenia in adults. J Hematol Oncol 2023; 16: 4. pmid:36658588 PubMed
- Stabell N, Bechensteen AG, Zeller B, et al. Akutt trombocytopeni. Akuttveileder i pediatri. Sist oppdatert 01.01.2021. Siden lest 21.06.2024 www.helsebiblioteket.no
- Grainger JD, Locatelli F, Chgotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): A randomised, multicentre, placebo-controlled trial. Lancet 2015. DOI: 10.1016/S0140-6736(15)61107-2 DOI
- Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Hematology 2015; 2: e71-e85. doi:10.1016/S2352-3026(15)00003-4 DOI
- Tarantino MD, Bussel JB, Blanchette VS, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016; 388: 45-54. doi:10.1016/S0140-6736(16)00279-8 DOI
- Iversen PO, Sandset PM. Norsk legemiddelhåndbok, sist endret 07.03.2016. legemiddelhandboka.no
- Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 2002; 141: 683-8. pmid:12410198 PubMed
- BlanchetteV, Freedman J, Garvey B. Management of chronic immune thrombocytopenic purpura in children and adults. Semin Hematol 1998; 35: 36-51. PubMed
- Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237-47. New England Journal of Medicine
- Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelets count and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 641-8. PubMed
- Wong RSM, Saleh MN, Khelif A et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 2017; 130: 2527-36. pmid:29042367 PubMed
- Arnold DM1, Dentali F, Crowther MA et al.. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146: 25-33. pmid:17200219 PubMed
- Waleed Ghanima, Pål André Holme, Geir E. Tjønnfjord. Immune thrombocytopenia--pathophysiology and treatment. Tidsskr Nor Laegeforen 2010; 130: 2120-3. pmid:21052113 PubMed
- Vianelli N, Galli M, de VA, Intermesoli T et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005; 90: 72-7. PubMed
- Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications.. Blood 2004; 104: 2623-34. pmid:15217831 PubMed